AC Immune SA (ACIU) AI Stock Analysis

• Market Cap: $300.79M
• Dividend Yield: N/A
• Average Volume (3M): 149.57K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.31
• Revenue Growth: 91.44%
• EPS Growth: 18.94%
• Country: US
• Employees: 133
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.26
• Shares Outstanding: 98,943,130
• 10 Day Avg. Volume: 176,186
• 30 Day Avg. Volume: 149,573
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.17
• Enterprise Value/Revenue: 1.75
• Enterprise Value/Gross Profit: 1.75
• Enterprise Value/Ebitda: -1.06
• 1Y Price Target: $10.00
• Price Target Upside: 219.49% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 51 Neutral
• Price Target: $2.00 ▼(-36.10% Downside)

AC Immune SA's stock score is primarily influenced by its financial performance and technical analysis. While the company shows potential with improving cash flow and short-term bullish momentum, persistent net losses and a negative P/E ratio weigh heavily on the overall score. The absence of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Revenue Growth

The significant revenue growth suggests AC Immune's products and partnerships are gaining traction, which could lead to sustainable long-term market presence and financial stability.

Strategic Partnerships

Strategic partnerships provide financial support and validation from larger pharmaceutical companies, enhancing AC Immune's ability to advance its drug candidates and expand its market reach.

Cash Flow Improvement

Improved cash flow management indicates better financial health, providing AC Immune with the resources to invest in R&D and support its long-term growth strategy.

Negative Factors

Profitability Challenges

Ongoing net losses hinder AC Immune's ability to achieve profitability, which may limit its capacity to reinvest in growth and innovation over the long term.

Operational Volatility

Volatile revenues and negative net income suggest instability in operations, which could affect AC Immune's ability to maintain consistent growth and investor confidence.

Debt Management

While the equity base is strong, accumulating losses could impact financial flexibility and strain resources needed for future growth and innovation.

AC Immune SA Business Overview & Revenue Model

Company Description

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

How the Company Makes Money

AC Immune generates revenue primarily through strategic partnerships and collaborations with larger pharmaceutical companies, which provide funding for the development of its drug candidates. These partnerships often include milestone payments, royalties on future sales, and upfront payments that contribute to the company's earnings. Additionally, AC Immune may receive revenue from licensing agreements related to its proprietary technologies. The company is also focused on advancing its own drug candidates through clinical trials, which, upon successful development and regulatory approval, can lead to significant sales revenue from these therapies in the market.

AC Immune SA Financial Statement Overview

Summary

AC Immune SA shows potential with increasing revenues and improved cash flow management in the latest period. However, consistent profitability remains a challenge due to persistent net losses. The balance sheet is stable with a strong equity position, but operational and financial volatility pose risks.

Income Statement

The company's revenue has shown significant volatility, with revenue increasing from 2022 to 2024. However, profitability remains a concern with negative net income and EBIT margins. The gross profit margin is positive in 2024, indicating some operational efficiency improvement, but net losses persist.

Balance Sheet

AC Immune SA maintains a strong equity base relative to its assets, with a manageable debt-to-equity ratio. However, the company has been accumulating net losses, affecting its return on equity. The equity ratio is healthy, indicating stability in capital structure.

Cash Flow

The cash flow situation shows improvement with a large positive free cash flow in 2024, albeit following a negative trend in prior years. The operating cash flow to net income ratio reflects better cash management, though sustainability remains a question due to historical volatility.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	28.92M	27.31M	14.80M	3.94M	0.00	15.43M
Gross Profit	28.92M	27.31M	-39.80M	-56.40M	-62.28M	-44.06M
EBITDA	-48.05M	-48.62M	-51.83M	-69.05M	-77.11M	-61.26M
Net Income	-50.51M	-50.92M	-54.23M	-70.75M	-73.00M	-62.10M
Balance Sheet
Total Assets	190.22M	230.91M	182.81M	185.94M	261.44M	238.74M
Cash, Cash Equivalents and Short-Term Investments	127.14M	165.49M	103.05M	122.59M	198.22M	225.89M
Total Debt	4.92M	5.43M	3.50M	2.80M	2.91M	2.22M
Total Liabilities	115.48M	118.64M	22.17M	16.95M	29.46M	23.26M
Stockholders Equity	74.74M	112.27M	160.64M	168.99M	231.98M	215.48M
Cash Flow
Free Cash Flow	-43.62M	65.27M	-61.21M	-74.81M	-68.32M	-61.22M
Operating Cash Flow	-42.62M	65.84M	-60.41M	-73.57M	-65.69M	-59.52M
Investing Cash Flow	21.00M	-105.29M	65.64M	23.76M	-53.66M	28.33M
Financing Cash Flow	-875.00K	-1.12M	43.25M	-1.35M	40.75M	-803.00K

AC Immune SA Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.13
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACIU, the sentiment is Positive. The current price of 3.13 is above the 20-day moving average (MA) of 2.60, above the 50-day MA of 2.35, and above the 200-day MA of 2.21, indicating a bullish trend. The MACD of 0.22 indicates Negative momentum. The RSI at 71.50 is Negative, neither overbought nor oversold. The STOCH value of 83.29 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ACIU.

AC Immune SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ALEC	56 Neutral	$303.64M	-2.71	-93.89%	―	46.78%	35.46%
ACIU	51 Neutral	$300.79M	―	-50.57%	―	91.44%	18.94%
EDIT	51 Neutral	$319.22M	-1.36	-176.57%	―	-41.97%	-20.86%
MLTX	41 Neutral	$479.16M	-2.67	―	―	―	-208.46%
FHTX	41 Neutral	$256.65M	-3.66	98.35%	―	-31.30%	36.26%
VOR	33 Underperform	$268.58M	-0.13	―	―	―	-686.12%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

AC Immune SA Corporate Events

AC Immune SA Announces Strategic Focus and Workforce Reduction

On September 4, 2025, AC Immune SA announced a strategic shift to focus on its key assets, including three clinical-stage active immunotherapy programs and promising small molecule programs targeting NLRP3 and Tau. This decision, following an executive management review, involves a 30% workforce reduction and is expected to extend the company’s cash runway to the end of Q3 2027. The move aims to enhance operational efficiency and maintain progress on clinical milestones, while also supporting affected employees through severance packages and job-seeking assistance.

AC Immune SA Reports Increased Losses in Mid-2025 Financial Results

AC Immune SA released its interim financial results for the three and six months ending June 30, 2025, reporting a significant operating loss compared to the previous year. Despite an increase in contract revenue, the company faced substantial operating expenses, leading to a net loss for the period, which may impact its financial stability and investor confidence.